A Bioequivalence Study of Docetaxel for Injectable Emulsion (ANX-514) in Patients With Advanced Cancer.

Trial Profile

A Bioequivalence Study of Docetaxel for Injectable Emulsion (ANX-514) in Patients With Advanced Cancer.

Completed
Phase of Trial: Phase I

Latest Information Update: 14 Mar 2013

At a glance

  • Drugs Docetaxel (Primary)
  • Indications Advanced breast cancer; Cancer; Non-small cell lung cancer; Prostate cancer
  • Focus Pharmacokinetics; Registrational
  • Sponsors Mast Therapeutics
  • Most Recent Events

    • 29 May 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 29 May 2009 Actual end date (Apr 2009) added as reported by ClinicalTrials.gov.
    • 29 May 2009 Actual number of patients (39) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top